Lonza has introduced an enhanced product line aimed at tackling concerns around bias during blinded clinical trials. Capsugel DBcaps double-blinded capsules are designed to be used as an over-encapsulation tool during clinical phases to overcome the challenges of blinding products during trials.

Julien Lamps, Product Manager at Lonza said, “Capsugel DBcaps capsules have been specifically created to combat the main hurdles during double-blinded clinical trials. This opaque product has an extended capsule length and dual locking rings which mean that they are not only allowing a high visual coverage of the form that is placed inside, but also extremely hard to open without damaging the capsules and breaking the blind.

Capsugel DBcaps capsules can be used with medical devices, as well as for over-encapsulation of uniquely shaped dosage forms and comparator products. They are designed to offer a faster, more cost-efficient solution for companies who would otherwise have to produce placebo forms identical in shape and size to the candidate product.

Stephen Rode, Business Development Manager at Lonza said, “During clinical trials it is imperative that sponsor companies and contract research companies alike can have peace of mind that they are complying sufficiently with blinding regulations to ensure a smooth journey to market. By combining anti-tampering measures with a flexible and robust product, we have been able to develop a solution that will meet the needs of our customers globally.”